Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone Treatment (Part A) in Tuberous Sclerosis Complex-related Epilepsy Followed by Long-term Treatment (Part B)

NCT04285346 is registered in ClinicalTrials.gov with Marinus Pharmaceuticals as lead sponsor.

NCT NCT04285346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04285346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone Treatment (Part A) in Tuberous Sclerosis Complex-related Epilepsy Followed by Long-term Treatment (Part B)
Lead sponsor
Marinus Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
April 8, 2020
Completion date
August 30, 2022
Enrollment
23 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

tuberous sclerosis